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Simocyclinone D8 (SD8) is a potent DNA gyrase inhibitor produced by Streptomyces antibioticus Tü6040. The
simocyclinone (sim) biosynthetic gene cluster has been sequenced and a hypothetical biosynthetic pathway
has been proposed. The tetraene linker in SD8 was suggested to be the product of a modular type I polyketide
synthase working in trans with two monofunctional enzymes. One of these monofunctional enzymes, SimC7,
was proposed to supply a dehydratase activity missing from two modules of the polyketide synthase. In this
study, we report the function of SimC7. We isolated the entire ~72-kb sim cluster on a single phage artificial
chromosome clone and produced simocyclinone heterologously in a Streptomyces coelicolor strain
engineered for improved antibiotic production. Deletion of simC7 resulted in the production of a novel
simocyclinone, 7-oxo-SD8, which unexpectedly carried a normal tetraene linker but was altered in the
angucyclinone moiety. We demonstrate that SimC7 is an NAD(P)H-dependent ketoreductase that catalyzes
the conversion of 7-oxo-SD8 into SD8. 7-oxo-SD8 was essentially inactive as a DNA gyrase inhibitor, and the
reduction of the keto group by SimC7 was shown to be crucial for high-affinity binding to the enzyme. Thus,
SimC7 is an angucyclinone ketoreductase that is essential for the biological activity of simocyclinone.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Simocyclinone D8 (SD8) is a natural hybrid
antibiotic made by Streptomyces antibioticus
Tü6040. It consists of a chlorinated aminocoumarin
connected to an angucyclic polyketide via a tetraene
diester linker and a D-olivose deoxysugar [1] (Fig. 1).
SD8 is a potent inhibitor of supercoiling by DNA
gyrase, an enzyme that is essential in bacteria but is
absent from humans, making it an excellent target
for antimicrobial drugs, as illustrated by the clinically
important fluoroquinolones [2–4].
All known aminocoumarin antibiotics target bacterial
DNA gyrase, but their modes of action differ. The three
classical Streptomyces aminocoumarin antibiotics—
novobiocin, clorobiocin, and coumermycin A1—bind to
the GyrB subunit of DNA gyrase and inhibit ATPase
activity [5]. In contrast, SD8 binds to the GyrA subunitAuthors. Published by Elsevier Ltd. T
rg/licenses/by/4.0/).of DNA gyrase and prevents binding to DNA [6]. SD8
is a bifunctional antibiotic with the aminocoumarin and
angucyclic polyketide moieties at either end of the
molecule binding to two separate pockets on the
DNA-binding interface of GyrA [7,8]. The interaction
with GyrA shows positive cooperativity, with the
binding of one end of SD8 to its pocket promoting
binding of the other end to its pocket. Based on these
observations, it has been proposed that binding to
GyrA is initiated by the high-affinity angucyclic
polyketide, followed by improved binding of the low-
affinity aminocoumarin [9]. Because of the bifunctional
nature of simocyclinone, removal of either the amino-
coumarin or the angucyclic polyketide from the
antibiotic reduces its potency as a DNA gyrase
inhibitor by about 100-fold compared to SD8, which
inhibits DNA supercoiling at sub-micromolar concen-
trations (IC50 ~ 0.1–0.6 μM) [7,9].
his is an open access article under the CC BY license
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Fig. 1. Chemical structures of simocyclinone SD8, the major product of S. antibioticus Tü6040; 7-oxo-SD8, the major
product of the simC7 mutant; and MGD8N2A, a semi-synthetic analog lacking the angucyclinone polyketide moiety
(generated by chemical hydrolysis of SD8). The absolute stereochemistry of SD8 was determined from co-crystals with
SimR (PDB accession number 2Y30) [14] and E. coli DNA gyrase (PDB accession number 4CKL) [8]. The C-6, C-7, and
C-8 positions discussed in the text are numbered, and the structural difference between SD8 and 7-oxo-SD8 is highlighted
in red.
2193SimC7 Function in Simocyclinone BiosynthesisBased on the intermediates detectable in cultures
of S. antibioticus Tü6040, it seems that the biosyn-
thesis of SD8 starts with assembly of the angucyclic
polyketide, followed by the attachment of the D-oli-
vose deoxysugar, then the tetraene linker, and
finally the aminocoumarin (i.e., assembled from
right to left as drawn in Fig. 1) [10]. Accordingly,
simocyclinone intermediates are classified into four
groups (A–D), with A-group intermediates having
only the angucyclic polyketide moiety, B-group
intermediates having the angucyclic polyketide
linked to the D-olivose deoxysugar, and so on [10].
The 49-gene simocyclinone (sim) biosynthetic
cluster of S. antibioticus Tü6040 has been se-
quenced and a hypothetical biosynthetic pathway
has been proposed [11,12]. Although two sim cluster
transcriptional regulators have been studied [13–16],
to date, only one biosynthetic enzyme has been
characterized. SimD5 (SimL) catalyzes the pre-
sumed last step in the pathway, functioning as an
amide-bond-forming ligase that attaches the amino-
coumarin to the tetraene linker [17–19].
Trefzer et al. proposed that the tetraene linker in
SD8 would be the product of a modular type I
polyketide synthase, SimC1ABC, working in trans
with twomonofunctional enzymes, SimC6 and SimC7
[11]. One of thesemonofunctional enzymes, SimC7, a
member of the short-chain dehydrogenase/reductase
(SDR) superfamily, was proposed to supply the
dehydratase activity missing from two modules of
the polyketide synthase [11]. Here, we determine the
true function of SimC7 experimentally and show that itis an angucyclinone ketoreductase that is essential for
the antibiotic activity of simocyclinone.Results
Heterologous expression of simocyclinones
Although directed mutations have been success-
fully created in the SD8 producer, S. antibioticus
Tü6040 [11,12], this strain is particularly challenging
to manipulate genetically. As a consequence, we
instead chose to clone the sim gene cluster and
analyze it in a heterologous system. The whole sim
cluster was isolated on a single phage artificial
chromosome (PAC) clone (PAC-12I) after PCR
screening of a genomic library generated in Escher-
ichia coli according to a recently developed protocol
for working with large gene clusters [20]. Sequenc-
ing of the 95-kb insert in PAC-12I revealed the
presence of the whole minimal sim gene cluster,
consisting of 49 genes covering an ~72-kb region
(Fig. S1), flanked by genomic regions of ~19 kb and
4 kb on either side.
We conjugated PAC-12I from the methylation-
deficient E. coli strain ET12567 into the heterologous
host Streptomyces coelicolorM1152. This strain has
been engineered for improved heterologous produc-
tion and analysis of secondary metabolites by
deletion of endogenous secondary metabolic clus-
ters, resulting in a strain without antimicrobial activity
2194 SimC7 Function in Simocyclinone Biosynthesisand a much simplified extracellular metabolite profile
for high-performance liquid chromatography (HPLC)
and mass spectrometry analyses [21]. In addition, it
carries a point mutation in the rpoB gene (encoding
the RNA polymerase β-subunit) that causes a
pleiotropic increase in the level of expression of
secondary metabolic clusters [21]. PAC-12I strongly
impaired the growth and sporulation of M1152. In an
attempt to overcome this toxicity, we took advantage
of a plasmid (pIJ10480 [13]) that expresses the
simEx1 simocyclinone efflux pump gene from the
strong constitutive promoter ermEp*. This plasmid
was previously shown to increase the minimum
inhibitory concentration (MIC) of SD8 for Streptomy-
ces lividans from 2 μg/mL to 65 μg/mL [13]. To
improve heterologous production of simocyclinones,
we introduced pIJ10480 into M1152, resulting in
strain S. coelicolor M1152ex1. Overexpression of
simEx1 increased the MIC of SD8 for M1152 from
1 μg/mL to 100 μg/mL.
We introduced PAC-12I and an empty vector
control into the optimized heterologous host
M1152ex1 by conjugation. Overexpression of the
simEx1 simocyclinone efflux pump gene reduced the
toxicity of PAC-12I and M1152ex1 was used for all
further work. Strains were grown in a defined
production medium consisting of a basic nutrient
medium with L-glutamine (5.84 g/L) and glycerol
(20 mL/L) as nitrogen and carbon sources, respec-
tively [10]. SD8 production in the heterologous hostFig. 2. LC-MS-UV analysis of simocyclinones produced by e
S. coelicolor M1152ex1. Chromatograms (200–700 nm) of cult
on PAC 12IΔsimC7 (top) and the complete sim cluster on P
(bottom), are shown. Molecular weights were confirmed by high
full tandem mass spectrometry data can be found in Fig. S3
medium.(24–56 mg/L) was 2- to 5-fold higher than that in the
natural producer S. antibioticus Tü6040 (9–14 mg/L).
No simocyclinones were detectable from M1152ex1
control strains lacking the sim gene cluster.
Structural analysis of a novel simocyclinone
intermediate
In order to determine the role of SimC7 in
simocyclinone biosynthesis, we created an in-frame
deletion in simC7 in PAC-12I using λ-Red PCR
targeting, and we introduced the resulting PAC clone
(PAC-12IΔC7) into M1152ex1. When fermentation
extracts of the resulting simC7 mutant strain were
analyzed by HPLC, the major biosynthetic product
had a later retention time than that of SD8 (Fig. 2).
The UV–vis spectrum of the new compound was
similar to that of SD8 but with reduced absorbance at
275 nm and a slight shift in the absorbance maxima
to 245 nm and 361 nm (Fig. S2). Unexpectedly, the
major product of the simC7mutant had a mass 2 Da
lighter than SD8. All of the A-, B-, and C-group
simocyclinone intermediates made by the simC7
mutant were also 2 Da lighter than the equivalent
molecules made by the wild-type sim cluster,
suggesting that the 2-Da difference lies in the
angucyclic polyketide and not in the tetraene linker.
Based on this observation, we predicted that one of
the five hydroxyl groups present in the angucyclic
polyketide moiety of SD8 remained as a carbonylxpression of the sim gene cluster in the heterologous host
ure extracts from clones carrying the simC7 mutant cluster
AC 12I (middle), alongside an isolated standard of SD8
-resolution mass spectrometry (parent peaks are indicated;
). Cultures were grown for 6 days at 30 °C in production
2195SimC7 Function in Simocyclinone Biosynthesisgroup in this molecule and that SimC7 acts as a
ketoreductase. To test this hypothesis, we purified
the new simocyclinone intermediate from 4 L culture
and determined its structure (63 mg isolated yield).
The molecular formula of the new compound was
determined using high-resolution mass spectrome-
try, which confirmed that it was missing two
hydrogen atoms {m/z (electrospray ionization) for
C46H40ClNO18: calculated, 930.2007; observed,
930.2009; Δ = 0.3 ppm [M + H]+} compared to
SD8 {m /z ( e l ec t r osp ray ion i za t i on ) f o rFig. 3. High-resolution tandem mass spectra for the sodium
are highlighted, consistent with the mass difference of 2 Da bC46H42ClNO18: calculated, 932.2163; observed,
932.2156; Δ = −0.8 ppm [M + H]+} (Fig. 2 and
Fig. S3). Tandem mass spectrometry analysis
revealed similar fragmentation patterns for the
new compound and SD8, with all of the ion
fragments containing the angucyclic polyketide
moiety having m/z ratios reduced by 2 Da com-
pared to SD8. Conversely, all ion fragments from
the new compound lacking the angucyclic polyke-
tide moiety had identical masses with those derived
from SD8 (Fig. 3).adducts of (a) SD8 and (b) 7-oxo-SD8. Selected fragments
eing located in the angucyclic polyketide moiety.
Fig. 4. Selected HMBC correlations for the angucyclic polyketide moiety of SD8 and of the new simocyclinone
intermediate 7-oxo-SD8. Key correlations for the C-7 position are depicted in red.
2196 SimC7 Function in Simocyclinone BiosynthesisExamination of the nuclear magnetic resonance
(NMR) spectra [attached proton test, correlated spec-
troscopy, total correlated spectroscopy, heteronuclear
single quantum coherence, and heteronuclear multiple
bond correlation (HMBC)] suggested that the new
molecule was structurally similar to SD8. However, the
H-6 proton was shifted downfield by 0.4 ppm and no
signal could be observed for the H-7 proton, consistent
with a structural change in the angucyclic polyketide
moiety (Fig. S4 and Table S1). Further analysis of the
2D (2-dimensional) NMR data enabled us to determine
the position of the structural change (Figs. 4 and 5 and
Figs. S5–S8). We confirmed appropriate proton–
proton correlations for H-5 and H-6, which were
supported by relevant proton–carbon correlations. In
addition, we identified a signal shifted downfield for C-7
in the 13C spectrum typical for a carbonyl group (Figs.
S9 and S10 and Table S2) and cross-peaks to a C-7
resonance could be identified in the HMBC experi-
ments (Fig. 4 and Fig. S7). From this, we concluded
that the product of the simC7 mutant had a carbonyl
group instead of a hydroxyl group at position C-7 in the
angucyclic polyketide. The new simocyclinone inter-
mediate was named 7-oxo-SD8 (Fig. 1).
Complementation of the simC7 mutant
To determine if the simC7 phenotype was caused
solely by loss of SimC7 function, we complemented
the mutant with an in trans copy of the gene. simC7
is the last gene of a putative seven-gene operon that
starts with simB7 (Fig. S1). Therefore, we drove
expression of simC7 from its putative native promot-
er by fusing simC7 directly to an ~400-bp fragment
spanning the intergenic region upstream of simB7,
and we cloned this fusion into the vector pGM1190.
Introduction of this construct restored SD8 produc-
tion to the simC7 mutant (data not shown).SimC7 is an NAD(P)H-dependent ketoreductase
that acts on the angucyclic polyketide
The fact that the simC7 mutant made 7-oxo-SD8
suggested that SimC7 is a ketoreductase involved in
biosynthesis of the angucyclic polyketide moiety and is
not a dehydratase that acts during formation of the
tetraene linker as had been proposed previously [11].
To test this hypothesis, we overexpressed an N-termi-
nally His-tagged version of SimC7 in E. coli and
assayed the purified recombinant protein for its ability
to use 7-oxo-SD8 as a substrate. Both the substrate
and the product of the reaction have strong chromo-
phores with only minor differences in their absorbance
spectra, and because their spectra also overlap those
of NAD(P)+/NAD(P)H, it was not possible to assay
SimC7 using spectrophotometric methods. Instead, we
followed the reaction by HPLC-UV (with SD8 as a
standard) and found that SimC7 readily converted
7-oxo-SD8 into SD8 (Fig. 6b). SimC7 was able to use
NADH or NADPH for the reduction (Fig. 6b) but
showed a preference for NADPH (data not shown). It
was also possible to assay the reaction in the reverse
direction, following the oxidation of SD8 to 7-oxo-SD8
by SimC7 (Fig. 6c). This reaction wasmuch slower and
required a very high concentration of the NAD+
cofactor (300 mM). In all cases, the identity of the
reaction product was confirmed by tandem mass
spectrometry.
The C-7 hydroxyl group is required for the
antibiotic activity of simocyclinone
The activity of 7-oxo-SD8 was tested in vivo and in
vitro. Wild-type E. coli and other Gram-negative
bacteria are resistant to simocyclinones because
the compounds cannot penetrate the outer mem-
brane [1]. We therefore employed an E. coli strain
Fig. 5. Shifted peaks and cross-peaks of SD8 (red) and 7-oxo-SD8 (blue) from 2D NMR (correlated spectroscopy and
heteronuclear single quantum coherence). 2D NMR maps are shown with projections of proton and carbon signals from
7-oxo-SD8. These are entirely consistent with the introduction of a carbonyl group at the C-7 position.
2197SimC7 Function in Simocyclinone Biosynthesis(NR698) that is sensitive to simocyclinones due to an
in-frame deletion in the imp (increased membrane
permeability) gene [22]. The MIC for SD8 was
0.3 μM. In contrast, NR698 grew in the presence of
7-oxo-SD8 at concentrations up to 17.5 μM, an
~60-fold increase in MIC.
The contrasting antibiotic activities of SD8 and
7-oxo-SD8 against whole cells suggested that the
oxidation state of the oxygen at the C-7 position
might be important for its ability to block DNA
supercoiling by DNA gyrase. We therefore tested
the activity of SD8 and 7-oxo-SD8 as DNA gyrase
inhibitors in vitro. In line with previous studies
[7,23,24], we found that SD8 inhibited supercoiling
by DNA gyrase with IC50 = 0.1–0.5 μM (Fig. 7a). Incontrast, 7-oxo-SD8 was almost 3 orders of magni-
tude less active (IC50 = 50–100 μM) (Fig. 7a).
The fluoroquinolone ciprofloxacin links DNA gyr-
ase to its substrate by stabilizing the DNA–protein
cleavage complex, leading to a characteristic “cleav-
age band” on gels (Fig. 7b) [4]. The presence of SD8
blocks DNA cleavage by gyrase by preventing the
enzyme from binding to DNA [7]. We tested the
ability of 7-oxo-SD8 to abrogate the ciprofloxacin--
stimulated cleavage of DNA by gyrase, using SD8 as
a control (Fig. 7b) [6]. As we found previously [7],
SD8 prevented DNA cleavage at low concentrations
(e.g., 0.5 μM), but we found that much higher
concentrations of 7-oxo-SD8 (N10 μM) were
required for inhibition of cleavage (Fig. 7b).
Fig. 6. Ketoreductase activity of SimC7. (a) SimC7 mediates conversion of the novel simocyclinone intermediate
7-oxo-SD8 (1) into SD8 (2). (b) NAD(P)H-dependent conversion of 7-oxo-SD8 into SD8 and (c) NAD(P)+-dependent
conversion of SD8 into 7-oxo-SD8, monitored by reversed-phase HPLC. Samples were incubated for 1 h at room
temperature. Reactions were stopped by quenching in methanol (1:1) and heat denaturation for 10 min at 100 °C.
2198 SimC7 Function in Simocyclinone BiosynthesisTo investigate the binding of 7-oxo-SD8 toGyrA, we
used surface plasmon resonance as described
previously [7]. We found that SD8 bound to the GyrA
N-terminal domain with a similar affinity to that
reported previously, but that only weak, non-specific
binding could be seen for the 7-oxo analog (data not
shown). Taken together, these data suggest that
7-oxo-SD8 binds gyrase 2–3 orders of magnitude
more weakly than SD8.
MGD8N2A is a simocyclinone analog (generated
by chemical hydrolysis of SD8) that lacks the
angucyclic polyketide (Fig. 1). This analog has
been tested previously and found to have greatly
reduced activity against DNA gyrase (IC50 = 50 μM)
in comparison to SD8 (IC50 = 0.1–0.6 μM) [7]. We
repeated these experiments with MGD8N2A and
obtained a similar value (IC50 = 25 μM). Thus,
comparing the IC50 values for 7-oxo-SD8 and
MGD8N2A, it is clear that the presence of a carbonylgroup at the C-7 position has a similarly negative
effect on the activity of simocyclinone as does
complete loss of the angucyclic polyketide.Discussion
To examine the prediction that SimC7 is a
dehydratase involved in the biosynthesis of the
tetraene linker, we isolated the ~72-kb sim gene
cluster on a single PAC clone and expressed
simocyclinone heterologously in an S. coelicolor
strain engineered for improved antibiotic production.
Deletion of simC7 from the PAC clone resulted in the
production of a novel simocyclinone, 7-oxo-SD8,
which unexpectedly carried a normal tetraene linker
but was altered in the angucyclinone moiety. We
went on to demonstrate that SimC7 is an NAD(P)H-
dependent ketoreductase that converts 7-oxo-SD8
Fig. 7. (a) Supercoiling and (b) cleavage relaxation assays with DNA gyrase in the presence of 7-oxo-SD8 or SD8. The
reaction mixtures contained E. coli DNA gyrase and varying concentrations of either SD8 or 7-oxo-SD8. For relaxation
assays, the mixtures were incubated without ATP and with ciprofloxacin (1 μM).
2199SimC7 Function in Simocyclinone Biosynthesisinto SD8 and that reduction of the keto group,
catalyzed by SimC7, is essential for the antibiotic
activity of simocyclinone.
Use of the S. coelicolor M1152 heterologous
expression system
Heterologous expression is a convenient tool for
structure–function analysis of secondary metabolites,
and improved derivatives of S. coelicolor and
Streptomyces avermitilis have recently been devel-
oped for this purpose [21,25,26]. Here, we demon-
strate the utility of this approach for the manipulation
and functional analysis of simocyclinone, an antibiotic
naturally made byS. antibioticus Tü6040, a strain that
is particularly challenging for genetic manipulation.
Despite the large size of the sim gene cluster (49
genes covering ~72 kb), it was straightforward to
isolate a PAC clone carrying the entire cluster and to
introduce it by conjugation into an engineered S.
coelicolor host, where the clone integrated irrevers-
ibly and replicated stably as part of the chromosome.
The same approach was recently used for the
successful heterologous expression in S. coelicolor
of the 83.5-kb FK506 gene cluster from Streptomyces
tsukubaensis [20]. The engineered S. coelicolor host
often gives a greater yield than the natural producer
[20,21], and this was also true for simocyclinone. A
further advantage of this approach is that genetic
modification of the target cluster can be carried out in
E. coli, giving full access to the advanced recombi-
neering tools available in this host. The explosion ofwhole genome sequencing has revealed tens of
thousands of new secondary metabolic gene
clusters [27,28], many in rare and difficult-to-culture
actinomycetes for which no genetic tools have been
developed. As a consequence, the heterologous
expression approach exemplified here is an attrac-
tive option for characterizing many of these clusters
and is likely to be of increasing importance in the
future.
The biochemical function of SimC7
SimC7 was proposed to be a dehydratase
involved in the biosynthesis of the tetraene linker
[11], but we have demonstrated that SimC7 is
actually an NAD(P)H-dependent ketoreductase that
reduces a carbonyl group at the C-7 position of the
angucyclic polyketide moiety. The fermentation
product of the simC7mutant, 7-oxo-SD8, was almost
inactive as a DNA gyrase inhibitor, showing that
reduction of the 7-oxo functional group by the
ketoreductase activity of SimC7 is essential for the
biological function of simocyclinones. Although
SimC7 readily converts 7-oxo-SD8 into SD8, syn-
thesis of the angucyclic polyketide is normally
completed before it is linked to the D-olivose sugar
and the other moieties of simocyclinone [10]. This
means that the natural substrate of SimC7 would be
an A-group intermediate (i.e., one having only the
angucyclic polyketide moiety) carrying a C-7 car-
bonyl. This species was detected neither in the
native producer S. antibioticus [10–12] nor in the
2200 SimC7 Function in Simocyclinone Biosynthesisheterologous host carrying the wild-type sim cluster,
but as expected, a species with the appropriate
mass was detected among the intermediates made
by the simC7 mutant. Having determined the true
function of SimC7, it remains unclear how the
tetraene linker of simocyclinone is assembled and
how dehydration takes place.
SimC7 (30 kDa; 284 amino acids) is a member of
the SDR family, one of the largest protein superfam-
ilies, having more than 120,000 representatives in
the databases. SDR proteins are diverse, with low
overall amino acid sequence identity (typically 20–
30% in pairwise comparisons), and they are princi-
pally characterized by the presence of a predicted
pyridine nucleotide-binding Rossmann fold, com-
prising a parallel β-sheet flanked by three helices on
each side. SDR proteins also have diverse biochem-
ical activities, including acting as dehydratases,
reductases, dehydrogenases, decarboxylases, and
epimerases [29,30]. Despite its function as an
angucyclinone ketoreductase, based on sequence
identity, SimC7 seems to be most similar to various
SDR sugar epimerases, and SimC7 secondary and
tertiary structure predictions using the Phyre2 server
[31] also show highest similarity to sugar-modifying
enzymes, such as epimerases, reductases, and
dehydratases. No close homologs in the databases
are known to function as ketoreductases.
Although none is closely related to SimC7, several
SDR ketoreductases have been identified that act onFig. 8. The angucyclic polyketide binding pocket in
GyrA, as revealed in the crystal structure of the GyrA–SD8
complex (PDB accession number 4CKL) [8]. SD8 is
contacted by residues from both GyrA subunits; those
from one subunit are shown in red and those from the other
subunit are shown in blue. For clarity, all hydrogens have
been omitted.polyketides. These include SDR proteins that reduce
the carbonyl group at position C-9 in the biosynthetic
pathways for jadomycin (JadE), actinorhodin
(ActKR), and hedamycin (HedKR) [32–34] and the
SDR protein that reduces the carbonyl group at
position C-6 in the landomycin pathway (LanV) [35].
Close homologs of these enzymes are encoded in
the sim gene cluster, raising the possibility that
SimA6 and SimA9 function to reduce the angucycli-
none C-10 and C-6 carbonyl groups, respectively,
during the biosynthesis of simocyclinone.SimC7 function is vital for producing
simocyclinones with antibiotic activity
Why does such a small structural change render
7-oxo-SD8 effectively inactive as a DNA gyrase
inhibitor? The crystal structure of the GyrA–SD8
complex revealed how DNA gyrase binds the
angucyclic polyketide [8] (Fig. 8). The C-6 hydroxyl
group makes a hydrogen bond to Met120, the C-7
hydroxyl group makes hydrogen bonds to Pro79 and
Arg121 (via a water molecule), and the C-8 hydroxyl
group makes hydrogen bonds to His80 and Arg121.
One speculative possibility is that the presence of a
C-7 carbonyl group in 7-oxo-SD8 leads to the
formation of intramolecular hydrogen bond with the
neighboring C-8 hydroxyl group, thus simultaneously
breaking contacts with His80 and a highly coordinat-
ed water molecule held in place by Pro79 and Arg121
(Fig. 8). His80 in particular seems to play a crucial role
in binding simocyclinone, as the SD8 IC50 is
increased 230-fold when this residue is mutated to
alanine [7]. In addition, the presence of a carbonyl
group at C-7 will alter the conformation of the
angucyclic polyketide, which may affect other bond-
ing interactions with GyrA. Thus, the introduction of a
carbonyl group at C-7 is likely to break several
hydrogen bonds that secure the angucyclic polyke-
tide in its binding pocket.Materials and Methods
Strains, plasmids, and oligonucleotides
Strains, plasmids, and oligonucleotides used in this work
are shown in Tables S3, S4, and S5, respectively.Antibiotic selection
Apramycin (50 μg/mL), carbenicillin (100 μg/mL), chlor-
amphenicol (25 μg/mL), hygromycin (40 μg/mL), kana-
mycin (50 μg/mL), nalidixic acid (25 μg/mL), and
thiostrepton (60 μg/mL) were added to solid media as
required unless otherwise noted. These concentrations
were halved in liquid cultures.
2201SimC7 Function in Simocyclinone BiosynthesisPAC library construction
A genomic library of S. antibioticus Tü6040 DNA was
constructed by Bio S&T Inc. (Montreal, Canada) as
described in Ref. [20], using the phage P1-derived
artificial chromosome (PAC) vector pESAC13†, a deriva-
tive of pPAC-S1 [36]. The integrative vector pESAC13
conferred kanamycin resistance in E. coli and thiostrepton
resistance in Streptomyces. Genomic DNA was isolated
and cloned between the two BamHI sites of pESAC13,
replacing the carbenicillin resistance gene. The genomic
DNA library consisted of 2688 individual PAC clones with
an average insert size of 110 kb (more than 20× genome
coverage).Identification of PAC clones containing the complete
sim gene cluster
The S. antibioticus PAC library was screened with two
primer pairs (Table S5) amplifying fragments flanking the
sim gene cluster. The screening identified six double-positive
clones with amplification of both PCR products. One
double-positive clone (PAC-12I; Table S4) was sequenced.
The insert in PAC-12I contained the minimal 72-kb sim gene
cluster flanked by genomic regions of ~19 kb and 4 kb on
either side (a total insert size of 95 kb), and PAC-12I was
chosen for heterologous expression studies.
Deletion of simC7 from PAC-12I and in trans
complementation
The simC7 gene was deleted by PCR targeting
according to standard protocols [37,38], leaving an 81-bp
in-frame scar. The PAC mutant (PAC-12IΔC7) structure
was confirmed by PCR and restriction digestion with
EcoRI. For complementation, simC7 was fused to the
simB7 promoter and cloned into pGM1190. Complemen-
tation of simC7 was confirmed by liquid chromatography
mass spectrometry (LC-MS).Mobilization of PAC clones
PAC clones were conjugated from E. coli DH5α into the
methylation-deficient E. coli strain ET12567 by triparental
mating, using E. coli TOP10 cells carrying the driver
plasmid pR9406 to mobilize the PAC [20]. PAC clones
were conjugated from E. coli ET12567(pR9406) into
S. coelicolor M1152 and M1152ex1 as previously de-
scribed [39]. After 16–20 h of incubation on R2 medium
without sucrose, plates were overlaid with thiostrepton and
nalidixic acid. Exconjugants were streaked on Mannitol
Soy Flour medium with thiostrepton and nalidixic acid. For
spore preparation, strains were grown on Instant Mashed
Potato Agar (2 g/L Smash® instant mashed potato and
2 g/L LabM agar, made up with tap water).Production medium and purification of simocyclinones
To optimize production of D-group simocyclinones, we
cultured strains for 6 days at 30 °C and 250 rpm in thebasal chemically defined medium described in Ref. [10],
supplemented with L-glutamine (5.84 g/L) as nitrogen
source and glycerol (20 mL/L) as carbon source. The
fermentation broth was acidified with HCl (5 M) to pH 4
and simocyclinones were extracted with an equal volume
of ethyl acetate. After centrifugation, the organic layer was
evaporated in vacuo. For the purification of 7-oxo-SD8, the
dried extract from 4 L culture medium (~1.5 g with ~15%
compound) was dissolved in methanol, filtered through
glass wool and purified by normal-phase liquid chroma-
tography on a silica column (Biotage® SNAP cartridge
KP-SIL 50 g, 40- to 65-μm particle size, 39 mm × 81 mm)
using a gradient elution from CH2Cl2-MeOH (95:5) to
CH2Cl2-MeOH (70:30) over 4 h at a flow rate of 50 mL/h
[40]. Fractions of 10 mL were collected and the presence
of the compound was verified by thin layer chromatogra-
phy and LC-MS. Selected fractions were pooled, dried in
vacuo, and tritiated in acetone. The acetone-soluble
fraction was dried and dissolved in methanol for size-
exclusion chromatography using Sephadex LH-20 (18- to
111-μm particle size) (Sigma-Aldrich). Following elution
using methanol, we collected fractions and confirmed the
presence of the compound by LC-MS. Fractions contain-
ing 7-oxo-SD8 were combined, the solvent was removed
under reduced pressure, and the concentrate was
dissolved in a methanol–acetone mix (1:1) and purified
further by preparative HPLC. After freeze drying, we
obtained ~63 mg of the new simocyclinone derivative in
a fine yellow powder (yield, ~27%; purity, N98%).High-performance liquid chromatography
For analytical HPLC, samples (30 μL) were separated
on an HPLC column (Phenomenex Gemini-NX 3u C18
110A, 150 mm × 4.6 mm) using a linear gradient with
0.1% formic acid as mobile phase A and methanol as
mobile phase B. The gradient was either 25–95% or 75–
95% solvent B over 20 min at a flow rate of 1 mL/min.
Absorbance was recorded with a diode array detector at
210 nm, 230 nm, and 360 nm for simocyclinones and
535 nm as reference. For preparative HPLC, samples
(350 μL) were injected onto an HPLC column (Phenom-
enex Gemini-NX 5u C18 110A AXIA Packed,
150 mm × 21.20 mm) with a Phenomenex SecurityGuard
Prep Cartridge Holder Kit (21.20 mm) attached to a
Dionex UltiMate 3000 HPLC machine. Separation was
performed using a linear gradient with 0.1% formic acid as
mobile phase A and methanol as mobile phase B. The
gradient was 75–95% mobile phase B over 20 min at a
flow rate of 21 mL/min, and absorbance was recorded at
360 nm.Liquid chromatography mass spectrometry
Samples (10 μL) were injected onto an HPLC column
(Phenomenex Luna-C18 3uC18(2) 100A, 100 mm × 2 mm)
with a Phenomenex SecurityGuard Prep Cartridge Holder
Kit (2 mm), attached to a Thermo ion-trap LC-MS (LCQ
DECA XPlus). Separation was performed using a linear
gradient with 0.1% formic acid as mobile phase A and
methanol as mobile phase B. The gradient was 25–95%
mobile phase B over 20 min at a flow rate of 1 mL/min.
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Spectra were recorded on a Bruker Avance DRX-700
and Avance III 400 spectrometer at 298 K. Data were
processed and analyzed using TopSpin v3.2 software
(Bruker). Assignments were made from experiments
recorded on the DRX-700 spectrometer; 1H coupling
constants were determined using experiments from the
Avance III 400 spectrometer. Simocyclinones were dis-
solved in DMSO-d6.
Overexpression and purification of SimC7
simC7 was PCR amplified from PAC-12I using Q5 DNA
polymerase (New England Biolabs) and oligonucleotides
that introduced NdeI and BamHI sites (Table S5). The
PCR product was cloned into pJET1.2/blunt and then
sub-cloned into pET15b vector (Novagen) cut with NdeI
and BamHI. The resulting construct, pET15b-NB-C7, was
sequenced for errors (MWG Eurofins).
E. coli Rosetta (DE3)pLysS-competent cells (Novagen)
were transformed with pET15b-NB-C7 and grown at 25 °C
in LB containing chloramphenicol and carbenicillin. One
50-mL overnight culture was used to inoculate two 400-mL
main cultures that were grown to an OD600 of ~0.4. Protein
expression was induced with IPTG added to a final
concentration of 0.5 mM and cultures were grown for an
additional 16 h at 25 °C. Cells were harvested and lysed
by sonication in 40 mL fresh lysis buffer [50 mM Tris–HCl
(pH 8.0), 150 mM NaCl, 0.1% (v/v) Triton-X100, 0.5 mg
lysozyme, and complete ethylenediaminetetraacetic-acid-
free protease inhibitor (Roche)]. Cell debris was removed by
centrifugation, the supernatantwas incubatedwith 0.6 mLof
Ni-NTA agarose beads (Qiagen) for 30 min, and then the
resin was packed into a 5-mL polypropylene column
(Qiagen). Unbound proteins were removed with 200 mL
wash buffer [50 mM Tris–HCl (pH 8.0), 250 mM NaCl,
and 5% (v/v) glycerol] and His-tagged SimC7 was eluted in
2–3 mL elution buffer [50 mM Tris–HCl (pH 8.0), 50 mM
NaCl, 5% (v/v) glycerol, and 250 mM imidazole]. The
purified protein was dialysed overnight into storage buffer
[20 mMTris–HCl (pH 8.0), 150 mMNaCl, 5% (v/v) glycerol,
1 mMDTT, and 2 mM ethylenediaminetetraacetic acid] and
then frozen in liquid nitrogen and stored at −80 °C. Protein
concentrations were determined using Bradford reagent
(BioRad).
SimC7 ketoreductase assays
Ketoreductase assays were performed in reaction
mixtures consisting of substrate (25–200 μM), NAD(P)H
(0.3 mM) or NAD+ (300 mM), Hepes (50 mM, pH 7.2), and
enzyme (500 nM). Reactions were initiated with SimC7
and quenched at specific time points with equal volumes of
methanol. Stopped reactions were incubated for 10 min at
100 °C and centrifuged to remove precipitated protein
(13,000g for 10 min at 4 °C). SD8 formation was quantified
by analytical reversed-phase HPLC using a linear gradient
of 25–95% methanol over 20 min then 95% methanol for
5 min against 0.1% formic acid in water, and absorbance
was recorded at 360 nm. SD8 concentrations were
calculated by comparison with a standard curve (Fig.
S11), which was calculated from a serial dilution of SD8
prepared in methanol (0.25–70 μM) under the conditions
described above (7.5–2100 pmol).Minimum inhibitory concentrations
MICs were determined as described in Ref. [41]. E. coli
NR698 [22] was grown in Müller-Hinton broth for 16–20 h
at 37 °C and bacterial growth was measured photometri-
cally at 600 nm wavelength.
DNA gyrase assays
Assays were performed as described previously [6,8].
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